DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin,
Telaprevir) for the treatment of early chronic Hepatitis C Virus (HCV) infection.